Eli Lilly LLY
Pharmaceuticals (obesity & diabetes). Eli Lilly and Company, listed on NYSE.
Based on the FY2025 annual report (Jan 2025 – Dec 2025)
Eli Lilly's market cap is
about $1.221 trillion.
#10 by market cap among 289 companies, based on the Nov 5, 2026 close. FY2025 revenue was $65.179B.
- Share price (close)
- $1,364.73
- P/E ratio
- 59.5x
- Market cap
- $1.221T
- Revenue
- $65.179B
- Operating income
- —
- Net income
- $20.64B
- Free cash flow
- —
- Total assets
- $112.476B
- Dividends paid
- $5.384B
- Dividend per share
- $6.23
- Dividend yield
- 0.5%
- Shares outstanding
- 899,300,000 shares
Where the revenue went
Revenue is set at 100% and split into what went to costs, R&D, operating expenses and taxes, and what was left as profit.
- Cost of revenue17.0%
- R&D20.5%
- Other expenses23.1%
- Income taxes & other7.8%
- Net income31.7%
Profitability and stability
Each figure comes with its rank among 300 companies. The further right the dot, the higher the rank.
- Revenue growthHow much revenue grew from the previous fiscal year
- +44.7%
- #11 of 299
- Revenue grew sharply over the year. The median across 299 companies is +7.9%.
- Operating marginShare of revenue kept as profit from the core business
- —
- Not ranked
- The filing doesn't include the items needed to calculate this.
- Net marginShare of revenue left as profit after interest and taxes
- 31.7%
- #29 of 298
- After taxes, 31.7% of revenue was left as net income. The median across 298 companies is 14.0%.
- FCF marginShare of revenue left as cash after capital spending
- —
- Not ranked
- Free cash flow based on capital spending isn't calculated for financial companies.
- ROEHow much profit the company earned on shareholders' equity in a year
- 101.2%
- #15 of 276
- Equity is small, so ROE comes out very high. The median across 276 companies is 16.8%.
- Debt-to-equityLiabilities relative to equity. Lower means less debt
- 323.9%
- #193 of 244
- Liabilities are more than twice equity. The median across 244 companies is 159.6%.
Revenue and profit over time
Gray bars show revenue and the green part inside shows net income. The number above each bar is revenue (abbreviated) and the number below is net margin. Hover over a bar to see the exact amounts.
Where the cash went
Unlike profit, cash flow is money that actually came in and went out.
- Cash from operations$16.813B
- Dividends paid−$5.384B
For financial companies, loans and investments drive cash flow rather than capital spending, so FCF isn’t calculated.
Whose money funds the assets
The company's assets, split into borrowed money (liabilities) and shareholders' money (equity).
- Total assets$112.476B
- Total liabilities$85.941B
- Total equity$26.535B
- Cash and equivalents$7.268B
Compared with similar companies
Based on each company's latest annual report, so fiscal year ends may differ.
Compare in detail| Company | Annual revenue | Net income | Revenue growth | Operating margin | Net margin |
|---|---|---|---|---|---|
| Eli LillyLLY | $65.179B | $20.64B | +44.7% | — | 31.7% |
| Johnson & JohnsonJNJ | $94.193B | $26.804B | +6.0% | — | 28.5% |
| AbbVieABBV | $61.16B | $4.226B | +8.6% | 24.6% | 6.9% |
| MerckMRK | $65.011B | $18.254B | +1.3% | — | 28.1% |
| PfizerPFE | $62.579B | $7.771B | −1.6% | — | 12.4% |
What the company does
Eli Lilly is the largest US drugmaker, known for the diabetes and obesity drugs Mounjaro and Zepbound, along with Alzheimer's and cancer treatments.
The fiscal year ends around December each year.
Related companies: Johnson & Johnson, AbbVie, Merck, Pfizer
Financial statements
Last 5 fiscal years. Currency: US dollars.
Show the table
| Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 28.3184B | 28.5414B | 34.124B | 45.043B | 65.179B |
| Cost of revenue | 7.3128B | 6.6298B | 7.082B | 8.418B | 11.052B |
| Gross profit | 21.0056B | 21.9116B | 27.042B | 36.625B | 54.127B |
| R&D expense | 6.9307B | 7.1908B | 9.313B | 10.991B | 13.337B |
| Pretax income | 6.1555B | 6.8064B | 6.554B | 12.68B | 25.731B |
| Net income | 5.5817B | 6.2448B | 5.24B | 10.59B | 20.64B |
| EPS (diluted) | $6.12 | $6.90 | $5.80 | $11.71 | $22.95 |
| Operating cash flow | 7.3659B | 7.5857B | 4.24B | 8.818B | 16.813B |
| Dividends paid | 3.0868B | 3.5358B | 4.069B | 4.68B | 5.384B |
| Total assets | 48.806B | 49.4898B | 64.0063B | 78.715B | 112.476B |
| Total liabilities | 39.8268B | 38.84B | 53.2344B | 64.443B | 85.941B |
| Total equity | 8.9792B | 10.6498B | 10.7719B | 14.272B | 26.535B |
| Cash and equivalents | 3.8185B | 2.067B | 2.8186B | 3.268B | 7.268B |
| Original filing | 10-K | 10-K | 10-K | 10-K | 10-K |
Source: SEC EDGAR filings for Eli Lilly and Company · CIK 0000059478 · US-GAAP